Nature Communications (Aug 2021)

A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity

  • Krishna Das,
  • Elodie Belnoue,
  • Matteo Rossi,
  • Tamara Hofer,
  • Sarah Danklmaier,
  • Tobias Nolden,
  • Liesa-Marie Schreiber,
  • Katharina Angerer,
  • Janine Kimpel,
  • Sandra Hoegler,
  • Bart Spiesschaert,
  • Lukas Kenner,
  • Dorothee von Laer,
  • Knut Elbers,
  • Madiha Derouazi,
  • Guido Wollmann

DOI
https://doi.org/10.1038/s41467-021-25506-6
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 14

Abstract

Read online

Successful cancer immune therapy correlates with a T cell-inflamed tumour microenvironment. Authors show here that co-administration of a self-adjuvanting protein vaccine and an antigen-expressing oncolytic virus in an optimised regimen strongly enhances T cell immunogenicity and may turn non-inflamed tumours proinflammatory and less resistant to checkpoint blockade therapy.